Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions

Obesity significantly exacerbates the symptoms of Polycystic Ovary Syndrome (PCOS) and increases the risk of long-term health issues. Current pharmacological treatments for obesity in PCOS, such as Metformin, Orlistat, Liraglutide, and Tirzepatide, are limited in effectiveness, prompting exploration of emerging therapies like Semaglutide and Cagrilintide. These therapies target mechanisms like insulin resistance and appetite regulation but require further study for safety and efficacy. The review emphasizes the importance of combining lifestyle interventions with pharmacological treatments and calls for personalized approaches and further research into combination therapies and novel agents to improve outcomes for women with PCOS.